Corcept Therapeutics (NASDAQ:CORT) Insider Sean Maduck Sells 75,000 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Sean Maduck sold 75,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $65.59, for a total value of $4,919,250.00. Following the completion of the sale, the insider owned 8,977 shares in the company, valued at approximately $588,801.43. This represents a 89.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Corcept Therapeutics Price Performance

CORT opened at $69.49 on Friday. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $91.00. The stock has a market cap of $7.46 billion, a P/E ratio of 198.55 and a beta of 0.36. The stock’s 50 day moving average price is $48.02 and its 200 day moving average price is $52.30.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.19). Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The business had revenue of $164.90 million during the quarter, compared to analyst estimates of $185.83 million. During the same quarter in the prior year, the business earned $0.17 earnings per share. The firm’s revenue was up 4.9% compared to the same quarter last year. Equities analysts anticipate that Corcept Therapeutics Incorporated will post 0.53 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on CORT. UBS Group set a $135.00 target price on Corcept Therapeutics in a research report on Thursday. Wolfe Research upgraded Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday, March 26th. Canaccord Genuity Group lifted their price target on Corcept Therapeutics from $110.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday. Truist Financial upgraded Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Zacks Research upgraded Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Corcept Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $88.83.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord Genuity raised its price target on Corcept Therapeutics to $135 from $110 and reiterated a buy rating, signaling greater confidence in upside potential. Canaccord Genuity price target update
• Positive Sentiment: HC Wainwright lifted its 2026 earnings estimates for CORT, including higher Q3, Q4, and full-year EPS forecasts, while maintaining a buy rating and $95 target. Higher profit expectations often support the stock. HC Wainwright estimate revisions
• Positive Sentiment: Corcept said it plans to resubmit the NDA for relacorilant in Cushing’s syndrome, which keeps a key pipeline asset alive and appears to be the main business-specific catalyst behind the recent rally. Relacorilant NDA resubmission article
• Neutral Sentiment: Stockholders approved an expanded incentive plan and board-related matters at the 2026 annual meeting; this is supportive of governance but not a major immediate earnings driver. Stockholders approve expanded incentive plan and board

Hedge Funds Weigh In On Corcept Therapeutics

Several hedge funds have recently modified their holdings of CORT. Torren Management LLC acquired a new position in shares of Corcept Therapeutics during the 4th quarter valued at $25,000. Advisory Services Network LLC bought a new stake in shares of Corcept Therapeutics during the 3rd quarter worth $25,000. Clearstead Advisors LLC boosted its stake in shares of Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 193 shares in the last quarter. Atlas Capital Advisors Inc. bought a new stake in shares of Corcept Therapeutics during the 4th quarter worth $31,000. Finally, State of Wyoming boosted its stake in shares of Corcept Therapeutics by 29.5% during the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 186 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.